1-5 of 5
James Liang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

Joachim R. Goethert, Harinder Gill, Francesca Palandri, David M. Ross, Tara Cochrane, Stephen R. Larsen, Anna B. Halpern, Jake Shortt, James M. Rossetti, James Liang, Monia Marchetti, Andrew J. Wilson, Andrew Innes, Merit Hanna, William S. Stevenson, Alessandro M. Vannucchi, Maria Kleppe, Georges Natsoulis, Claire N Harrison, Hugh Young Rienhoff Jr.
Journal: Blood
Blood (2023) 142 (Supplement 1): 747.
https://doi.org/10.1182/blood-2023-179329
Published: 2023
Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

Harinder Gill, Francesca Palandri, David M Ross, Tara Cochrane, Courtney Tate, Steven W Lane, Stephen R Larsen, Aaron T. Gerds, Anna B. Halpern, Jake Shortt, James M. Rossetti, Kristen M. Pettit, James Liang, Adam J Mead, Monia Marchetti, Alessandro M. Vannucchi, Andrew J Wilson, Joachim R Göthert, Merit Hanna, Francesco Passamonti, William S Stevenson, Claire Harrison, Moshe Talpaz, Nicola Vianelli, Hugh Young Rienhoff, Jr.
Journal: Blood
Blood (2022) 140 (Supplement 1): 1784–1787.
https://doi.org/10.1182/blood-2022-159047
Published: 2022
Journal Articles

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

David M Ross, Alejandro Arbelaez, Lynette C.Y. Chee, Chun Yew Fong, Devendra Hiwase, George Kannourakis, John Kwan, James Liang, Anish Puliyayil, Hannah Rose, Shuhying Tan, Tse-Chieh Teh, David Alan Westerman, Joel Wight, Chris Rovaldi, Elissa M. Furutani, Adrienne Gaggi, Ying Jiang, Jenn Lachey, Harveen Dhillon Natarajan, Claudia Ordonez
Journal: Blood
Blood (2021) 138 (Supplement 1): 3675.
https://doi.org/10.1182/blood-2021-147335
Published: 2021
Journal Articles

Weekly Subcutaneous Bortezomib Is Well Tolerated and Effective As Initial Therapy Of Symptomatic Myeloma

David Simpson, MBChB, FRACP, FRCPA, Rory McCulloch, MBChB, James Liang, MBChB, Sarah Mant, Naomi Whyler, Liam J. Fernyhough, MB, BS,, BMedSci
Journal: Blood
Blood (2013) 122 (21): 3229.
https://doi.org/10.1182/blood.V122.21.3229.3229
Published: 2013
Journal Articles

Once Weekly Subcutanous Bortezomib with Cyclophosphamide and Dexamethasone Is Well Tolerated and Effective As Initial Treatment in Symptomatic Multiple Myeloma

David Simpson, FRACP, FRCPA, MBChB, James Liang, MBChB, Ross Henderson, MBChB, PhD, FRACP, FRCPA, Merit Hanna, MBChB, FRCPA, Eileen Merriman, MBChB, FRACP, FRCPA
Journal: Blood
Blood (2012) 120 (21): 4049.
https://doi.org/10.1182/blood.V120.21.4049.4049
Published: 2012